Fiche du document
- doi: 10.1093/neuonc/now182
- issn: 1522-8517
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/neuonc/now182
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/27664860
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1523-5866
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_1E5E2F0B24976
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Citer ce document
A.F. Hottinger et al., « Tumor treating fields: a novel treatment modality and its use in brain tumors. », Serveur académique Lausannois, ID : 10.1093/neuonc/now182
Métriques
Partage / Export
Résumé
Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomized phase 3 trials in glioblastoma (GBM) and demonstrated to prolong progression-free survival (PFS) and overall survival (OS) when administered together with standard maintenance temozolomide (TMZ) chemotherapy in patients with newly diagnosed GBM. TTFields are continuously delivered by 4 transducer arrays consisting each of 9 insulated electrodes that are placed on the patient's shaved scalp and connected to a portable device. Here we summarize the preclinical data and mechanism of action, the available clinical data, and further outlook of this treatment modality in brain tumors and other cancer indications.